



Prognostic Value and Potential Immunoregulatory
Role of SCARF1 in Hepatocellular Carcinoma




Creative Commons: Attribution (CC BY)
Document Version
Publisher's PDF, also known as Version of record
Citation for published version (Harvard):
Patten, DA, Wilkinson, AL, O'rourke, JM & Shetty, S 2020, 'Prognostic Value and Potential Immunoregulatory
Role of SCARF1 in Hepatocellular Carcinoma', Frontiers in Oncology, vol. 10, 565950.
https://doi.org/10.3389/fonc.2020.565950
Link to publication on Research at Birmingham portal
General rights
Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the
copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes
permitted by law.
•	Users may freely distribute the URL that is used to identify this publication.
•	Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private
study or non-commercial research.
•	User may use extracts from the document in line with the concept of ‘fair dealing’ under the Copyright, Designs and Patents Act 1988 (?)
•	Users may not further distribute the material nor use it for the purposes of commercial gain.
Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.
When citing, please reference the published version.
Take down policy
While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been
uploaded in error or has been deemed to be commercially or otherwise sensitive.
If you believe that this is the case for this document, please contact UBIRA@lists.bham.ac.uk providing details and we will remove access to
the work immediately and investigate.
Download date: 11. May. 2021
ORIGINAL RESEARCH
published: 29 September 2020
doi: 10.3389/fonc.2020.565950
Frontiers in Oncology | www.frontiersin.org 1 September 2020 | Volume 10 | Article 565950
Edited by:
Niccolò Bolli,
University of Milan, Italy
Reviewed by:
Anetta Härtlova,
University of Gothenburg, Sweden
Edward N. Harris,






This article was submitted to
Cancer Molecular Targets and
Therapeutics,
a section of the journal
Frontiers in Oncology
Received: 26 May 2020
Accepted: 26 August 2020
Published: 29 September 2020
Citation:
Patten DA, Wilkinson AL,
O’Rourke JM and Shetty S (2020)
Prognostic Value and Potential




Prognostic Value and Potential
Immunoregulatory Role of SCARF1 in
Hepatocellular Carcinoma
Daniel A. Patten*, Alex L. Wilkinson, Joanne M. O’Rourke and Shishir Shetty
National Institute for Health Research Birmingham Liver Biomedical Research Unit and Centre for Liver and Gastrointestinal
Research, Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, United Kingdom
Scavenger receptor class F member 1 (SCARF1) is thought to play an important role
in the selective recruitment of CD4+ T cells to liver sinusoidal endothelial cells during
chronic liver disease. However, the contribution of SCARF1 to hepatocellular carcinoma
(HCC) is currently unknown. We utilized publically-available RNA-sequencing data from
The Cancer Genome Atlas (TGCA) to explore SCARF1 expression in HCC and correlated
it with a number of clinicopathological features. Flow adhesion assays were used to
determine the role of SCARF1 in CD4+ T cell subset recruitment. SCARF1 expression
was downregulated in HCC tumor tissues, compared to non-tumoral tissues, and loss
of SCARF1 expression was associated with poorly differentiated/aggressive tumors.
Additionally, higher SCARF1 expression in HCC tumor tissues was highly prognostic
of better overall, disease-free and progression-free survival. SCARF1 within HCC was
largely associated with tumor endothelial cells and adhesion studies suggested that it
played a role in the specific recruitment of proinflammatory CD4+ T cells (CD4+CD25−)
to HCC tumor tissues. Endothelial SCARF1 expression in tumor biopsies may provide
critical prognostic information. Additionally, SCARF1 may also be a novel endothelial
target that could help re-programme the microenvironment of HCC by promoting effector
T cell tumor infiltration.
Keywords: scavenger receptor, leukocyte recruitment, tumor endothelial cells, liver cancer, tumor
microenviroment
INTRODUCTION
Globally, hepatocellular carcinoma (HCC) is the second most common cause of cancer-related
deaths and its incidence is predicted to further increase (1). Due to a combination of poor
surveillance and lack of conclusive biomarkers (2), a large majority of HCC patients present
with advanced disease and, consequently, current interventional therapies can only act to prolong
survival by a few months. In more than 90% of cases, HCC occurs on the background of
chronic liver disease/cirrhosis and thus provides a paradigm for inflammation-induced cancer
(3). It is well-known that tumor-infiltrating lymphocytes (TILs) significantly influence the tumor
microenvironment and their phenotype strongly influences prognosis in HCC (4–6); consequently,
immunotherapies for the treatment of HCC are receiving increasing attention in the literature
(7, 8). Present research is predominantly focussed on the efficacy of checkpoint blockade inhibitors
(CIs) to “remove the brake” on the immune system in order to provide an anti-tumoral
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immune response; however, recent success of CIs with anti–
vascular endothelial growth factor (VEGF) treatment has
highlighted the importance of the endothelium in the context of
immunotherapy (9). Only a subset of patients with HCC appear
to respond to immunotherapy, but selecting which patients
will benefit continues to be a challenge and the presence or
absence of TILs in HCC is likely to play a significant role in
the response to immunotherapy. Despite this, the endothelial
pathways and molecules involved in the entry of TILs to HCC
tumors are considerably understudied. Lymphocyte recruitment
to the liver occurs within the specialized low flow channels of
the sinusoids and via a sequential step-wise process known as
the “leukocyte adhesion cascade” (10). The leukocyte adhesion
cascade is mediated by a number of receptor-ligand interactions
between the lymphocytes and liver sinusoidal endothelial cells
(LSEC) and previous studies from our lab and others have
implicated members of the scavenger receptor super-family in
the recruitment of leukocytes to LSEC in vitro (11–16). We
have also shown that these endothelial-expressed scavenger
receptors are present within the sinusoids of HCC tumor
tissues (13, 14); however, their role in shaping the tumor
microenvironment via the recruitment of TILs has not been
studied to date.
Scavenger receptors are a large super-family of proteins
which are defined by their ability to bind and endocytose
a vast range of endogenous and exogenous ligands, eliciting
the “scavenging” of unwanted macromolecules from the
bloodstream (17). Functionally, scavenger receptors generally
play beneficial roles in tissue homeostasis and protective
roles during infection, but have also been implicated in the
persistence of inflammatory disorders, including chronic liver
diseases (17, 18) and cancers (19). Liver sinusoidal endothelial
cells (LSEC) express an array of scavenger receptors at high
density, a phenotype which is consistent with their primary
biological function of removing gut-derived antigens from the
portal blood (10). However, we have also reported that LSEC-
expressed scavenger receptors perform an important secondary
role in which they mediate the recruitment of leukocytes
to the liver (11).
Scavenger receptor class F, member 1 (SCARF1 or SR-F1),
also known as scavenger receptor expressed by endothelial cells
(SREC)-I, was first identified in cDNA libraries from human
umbilical vein endothelial cells (HUVEC) (20). SCARF1 has
been shown to bind and internalize modified low density
lipoproteins (LDLs), specifically acLDLs (21), and a wide range
of other endogenous damage-associated products (22), such
as heat-shock proteins (HSPs) (23–25) and apoptotic host
cells (26, 27). In addition to a diverse range of endogenous
ligands, SCARF1 also binds a wide array of viral (28–30),
fungal (31), and bacterial (32–35) antigens. Furthermore, our
lab was the first to comprehensively characterize SCARF1
expression in human liver tissues and primary LSEC and
we were able to demonstrate that SCARF1 plays a role in
the selective recruitment of CD4+ T cells to the sinusoidal
endothelium under physiological shear stress (14). In this
regard, we hypothesized that SCARF1 actively contributed to
the hepatic microenvironment and played an important role in
the pathophysiology of chronic inflammatory liver diseases and
malignancies (14).
Here, through the utilization of the publically-available
TGCA (The Cancer Genome Atlas) RNA-sequencing datasets
(http://cancergenome.nih.gov), we describe the differential
regulation of scavenger receptors in HCC tumor tissues,
compared to non-tumorous control tissues, and specifically
focussed on the downregulation of SCARF1 expression. We
corroborated these findings with immunohistochemical staining,
which also showed reduced protein expression in HCC tumor
tissues, and next explored the relationship of SCARF1 expression
with tumor progression. Consequently, we found an association
with loss of SCARF1 expression with aggressive tumor biology.
Following this, we evaluated the prognostic value of SCARF1
expression in HCC tumors by generating survival curve data,
via KM Plotter (http://kmplot.com/analysis/). In support of the
pathological findings, high SCARF1 expression in HCC tumor
tissues was found to correlate with a better overall survival,
disease-free survival and progression-free survival. Next, via a
combination of TGCA data analysis and immunofluorescent
staining, we determined that SCARF1 within HCC was largely
associated with tumor endothelial cells. Finally, we extended
our previous findings with primary human liver endothelial
cells by studying subsets of CD4+ T cells. Using flow-based
adhesion assays under physiological levels of shear stress
our findings suggested that SCARF1 could play a role in the
recruitment of proinflammatory CD4+ T cells (CD4+CD25−),
rather than immunosuppressive T cell subsets, to the HCC
tissue microenvironment. Our results demonstrate that SCARF1
could be a prognostic biomarker in HCC. Furthermore, SCARF1
expression could potentially be targeted to alter the inflammatory
status of the tumor microenvironment, shifting it toward an
anti-tumoral immune response and supporting immunotherapy
regimes for HCC.
MATERIALS AND METHODS
In silico Data Analysis
Publically-available data from the The Cancer Genome Atlas
(TGCA) was utilized throughout this study. To explore
scavenger receptor family expression in tumor and relevant
non-tumorous tissue controls from the TGCA dataset, the
University of California Santa Cruz (UCSC) Xena tool (https://
xenabrowser.net/) was used. Correlation of SCARF1 expression
with tumor progression/aggression and cell-specific markers was
performed via the cBioPortal website (https://www.cbioportal.
org/) (accessed 25th Feb 2020). With the use of the publically-
accessible tool KM Plotter (http://kmplot.com/analysis/),
survival data was generated from the TGCA dataset over a
60-month time period, with the data being split into two groups
(“High” and “Low”) by the median of SCARF1 expression.
Resultant data was exported to Prism R© 6 software (GraphPad
Software Inc.) and survival curves were produced. The Gene
Expression Profiling Interactive Analysis (GEPIA) website
(http://gepia.cancer-pku.cn/) was used to generate a list of the
top 25 genes regulated in conjunction with SCARF1 in HCC
tumor tissues. Level of CD4+ T cell infiltration of HCC tumors
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was correlated with SCARF1 expression via the Tumor IMmune
Estimation Resource (TIMER; https://cistrome.shinyapps.io/
timer/; accessed 12th May 2020).
Human Tissue Samples
All liver tissue samples were collected from patients
undergoing transplantation for chronic liver disease or
primary hepatocellular carcinoma (HCC) at the University
Hospitals Birmingham NHS Foundation Trust, with written
informed consent and local ethics committee approval.
All experiments were performed in accordance with
the regulations and guidelines sanctioned by the West
Midlands—South Birmingham Research Ethics Committee,
Birmingham, UK (LREC reference 06/Q2702/61 and
04/Q2708/41).
Immunohistochemistry
Immunohistochemical staining was performed on 7µm thick
acetone-fixed cryosections, stored at −20◦C. Prior to staining,
sections were thawed to room temperature (RT) and hydrated
with PBS/0.1% Tween R© 20 (PBST) for 5min. Endogenous
peroxidase activity was then blocked with 0.3% hydrogen
peroxide in methanol and blocking of non-specific binding
was performed by incubation with 2X Casein Solution (Vector
Laboratories, Inc.). Sections were incubated with anti-SCARF-
1 primary antibody (8µg/ml; Abcam; ab92308) diluted in PBS
for 1 h at RT and then washed twice in PBST for 5min.
Isotype matched controls at appropriate concentrations were
performed in all experiments. Subsequently, sections were
incubated with the anti-rabbit ImmPRESSTM HRP for 30min
at RT. Excess secondary antibody was washed off with PBST
for 5min (twice) and sections were then incubated with DAB
chromogen (Vector Laboratories Inc.) for 2min; the reaction was
stopped with the addition of distilled H2O. Nuclei were then
counterstained with Mayer’s Hematoxylin (Pioneer Research
Chemicals Ltd.) for 30 s and slides were washed in warm H2O
for 2min. Sections were subsequently dehydrated in sequential
washes of alcohol (3×) and xylene (3×) and mounted using
DPX (Phthalate-free) mounting medium (CellPath). Images
were taken using an Axio ScanZ1 microscope (ZEISS). Surface
area coverage of SCARF1 staining was performed by via
threshold analysis using ImageJ software. Five random high-
power fields of view were analyzed per section, with the
average value taken for each matched pair of tumor and non-
tumorous tissues.
Immunofluorescence
For immunofluorescent staining, 7µm acetone-fixed
cryosections were thawed and then blocked for non-
specific binding by incubation in PBS with 10% goat
serum and casein solution, for 30min at RT. This was
followed by 1 h incubation with primary antibodies for
SCARF-1 (8µg/ml, Abcam ab92308) and CD31 (5µg/ml,
DAKO JC70A). Samples were washed three times in PBS
followed by 30min incubation with Alexa Fluor R© conjugated
secondary antibodies (1:500 dilution; Thermo Fisher Scientific).
Nuclei were stained with 300 nM DAPI (Invitrogen) and
slides were subsequently mounted with ProLongTM Gold
Antifade Mountant (Invitrogen). Fluorescence images
were acquired using a Zeiss 780 Zen confocal fluorescence
microscope (ZEISS).
LSEC Isolation and Culture
Liver sinusoidal endothelial cells (LSEC) were isolated from
∼30 g human liver tissue as described previously (36). Briefly,
tissues were subjected to enzymatic digestion via collagenase
(10 mg/ml collagenase IA; Sigma-Aldrich) and non-parenchymal
cells were separated out via density gradient centrifugation
on a 33%/77% Percoll (GE Healthcare) gradient at 800 × g
for 25min. The relevant cell layer was then removed, and
LSEC were isolated by positive immunomagnetic selection
using CD31 antibody-conjugated DynabeadsTM (Invitrogen).
LSEC were then seeded in rat tail collagen (1 in 100; Sigma-
Aldrich)-coated culture vessels in medium composed of human
endothelial serum-free media (SFM; Invitrogen) supplemented
with 10% human serum (HD Supplies), 10 ng/ml vascular
endothelial growth factor (VEGF; PeproTech), and 10 ng/ml
hepatocyte growth factor (HGF; PeproTech). All cells were
grown and maintained at 37◦C in a humidified incubator with
5% CO2.
Primary Lymphocyte Isolation
Peripheral blood mononuclear cells (PBMCs) were isolated
from whole blood via density gradient centrifugation;
briefly, whole blood was layered on Lympholyte R©-H
(Cedarlane) and centrifuged at 800 × g for 25min.
The PBMC layer was removed and washed in PBS with
2% FCS and 1mM EDTA (GibcoTM by Thermo Fisher
Scientific) and centrifuged at 800 × g for 5min. A platelet
depletion step was then performed by a second wash in
PBS with 2% FCS and 1mM EDTA and centrifugation
at 350 × g for 10min. CD4+CD25+ T lymphocytes
were subsequently isolated from PBMCs by DynabeadsTM
Regulatory CD4+/CD25+ T Cell Kit, and in accordance
with manufacturer’s instructions. The CD4+/CD25− fraction
obtained via this isolation protocol was kept and used as
an “effector” population in flow-based adhesion assays, as
previously described (13).
Flow-Based Adhesion Assays
Flow-based adhesion assays over monolayers of LSEC (13, 37)
were used to study lymphocyte recruitment in vitro, under
conditions of physiological flow. Briefly, approx. 7.5 × 105
LSEC were seeded in rat tail collagen-coated µ-slide VI 0.4
and grown to confluence overnight. Cells were then stimulated
with 10 ng/ml TNFα for 24 h to induce endothelial activation.
CD4+CD25+ or CD4+CD25− T lymphocytes were isolated
(see ‘Primary Lymphocyte Isolation’ above) and resuspended
at a cell density of 1 × 106 cells/ml in a flow medium
of Endothelial SFM with 0.1% BSA. Lymphocytes were then
perfused over the LSEC at a physiological shear of 0.05 Pa, with
each channel of the µ-slide perfused for 5min. Subsequently,
channels were washed though for 3min with flow media
alone, after which video recordings were taken. All flow
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FIGURE 1 | SCARF1 gene and protein expression is downregulated in HCC tumors. (A) Regulation of scavenger receptor gene expression in HCC tumors (blue; n =
371), compared to non-tumoral tissues (red; n = 162). *, **, *** and **** are representative of statistical significance as measured by the Kruskal–Wallis test, where p ≤
0.05, p ≤ 0.01, p ≤ 0.005, and p ≤ 0.001, respectively. RSEM = RNA-Seq by Expectation Maximization. (B) Comparison of SCARF1 gene expression in non-tumoral
(NT) tissues with HCC tumor tissues (T). ****Indicates statistical significance as measured by Mann–Whitney U-test, where p ≤ 0.001 (C). Representative images of
SCARF1 immunohistochemical staining (brown) in HCC tumor (Right panels) and matched distal, non-tumorous (Left panels) tissues from the same patient. Scale bar
= 400µm; zoomed image scale bar = 100µm. (D) Surface area quantification of immunohistochemical staining in matched HCC tumor (T) and non-tumorous (NT)
tissues was performed by via threshold analysis using ImageJ software. **Indicates statistical significance as measured by a paired T-test, where p ≤ 0.01. n = 5, with
the average of 5 random high-power fields of view taken per section. Data in (A,B) was generated from the TGCA dataset using the University of California Santa Cruz
(UCSC) Xena tool (https://xenabrowser.net/).
assays were imaged via phase-contrast microscopy on an
Olympus IX50 Inverted Microscope (Olympus) and 12 frames
from each channel were analyzed. The number of adherent
lymphocytes was firstly counted and then normalized to
cells/mm2/106 cells perfused using the following equation:
adherent cells/flow rate (0.28 ml/min) × bolus (5min) ×
field of view area (0.154 mm2) × (1/ concentration of
lymphocytes 1 × 106 cells/ml). The addition of SCARF-
1 blocking antibody (10µg/ml; Abcam; ab92308) or rabbit
polyclonal negative control (10µg/ml; DAKO) was performed
immediately preceding each assay and incubated for 30
min (14).
Statistical Analyses
All data were tested for normal distribution by the D’Agostino-
Pearson omnibus test. All data were found to be non-parametric
and so were expressed as median ± interquartile range
(IQR), with the number of experimental repeats (n)
specified in each case. For single comparisons, statistical
significance was determined by Mann–Whitney U-test,
whereas evaluation of multiple treatments was performed
by Kruskall–Wallis one-way analysis of variance with post
hoc Dunn’s test. Statistical significance of paired data was
calculated via a paired T-test. A p-value of ≤ 0.05 was
considered as statistically significant. All statistical analyses
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FIGURE 2 | More advanced and aggressive tumors exhibit lower SCARF1 expression. (A) SCARF1 expression in HCC tumor tissues of different histological grade.
* and ** are representative of statistical significance as measured by the Kruskal–Wallis test, where p ≤ 0.05 and p ≤ 0.01, respectively. (B) SCARF1 expression in
HCC tumor tissues from the four cancer stages. **indicates statistical significance as measured by the Kruskal–Wallis test, where p ≤ 0.01. SCARF1 expression
correlated to tumor aggression parameters (C). Aneuploidy score (n =355) and (D) Buffa Hypoxia score (n = 361). Data in this Figure was generated from the TGCA
dataset using the cBioPortal website (https://www.cbioportal.org/) (accessed 25th Feb 2020).
were undertaken using Prism R© 6 software (GraphPad
Software Inc.).
RESULTS
SCARF1 Expression Is Downregulated in
HCC Tumors
A number of scavenger receptors have previously been shown
to be significantly dysregulated within tumor tissues and have
consequently been implicated in the pathophysiology of a wide
variety of cancers (19). Here, we explored the mRNA expression
of the scavenger receptor super-family in HCC and highlight that
a number of members exhibited differential regulation in tumor
tissues, compared to non-tumorous control tissues. Interestingly,
themajority of scavenger receptors (MARCO, SCARA5,CLEC7A,
MRC1, SCARF1, SCARF2, STAB1, STAB2, CD163, AGER)
demonstrated significantly decreased expression in HCC tumor,
compared to non-tumorous liver tissues (Figure 1A). However,
in contrast, SCARA3, COLEC12, and CD68 were all up-regulated
(Figure 1A) and several others (MSR1, CD36,OLR1, ASGR1, and
CXCL16) did not exhibit any regulation (Figure 1A). Of those
significantly regulated, we were particularly interested in those
previously implicated in leukocyte recruitment to the liver and
specifically focussed on SCARF1 in the current study.
Utilizing qPCR analysis, we have previously shown a
strong trend for decreased SCARF1 mRNA expression
in HCC tumor tissue compared to normal liver tissue
(14); here, we corroborated this finding with publically-
available RNA-sequencing data from The Cancer Genome
Atlas (TGCA). Analysis of the TGCA data showed that
SCARF1 expression is significantly (p ≤ 0.001) lower in
HCC tumor tissues in comparison to non-tumorous tissues
(Figure 1B). In addition, SCARF1 expression is also reduced
in tumor tissues of other gastrointestinal cancers, namely
esophageal carcinoma, stomach adenocarcinoma and colon
adenocarcinoma, compared to their respective non-tumorous
tissue controls (Figure S1). Interestingly, and in contrast to the
other cancer types explored here, pancreatic adenocarcinoma
tumors showed no dysregulation of SCARF1 expression
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FIGURE 3 | SCARF1 expression is predictive of survival in HCC. (A) Overall survival, (B) Disease-free survival, and (C) Progression-free survival of HCC patients
separated into two groups (“High” and “Low” expression) via the median expression of SCARF1. *, ** and *** indicate statistical significance where p ≤ 0.05, p ≤ 0.01,
or p ≤ 0.005, respectively. HR = hazard ratio. Forest plots of (D) Overall survival, (E) Disease-free survival, and (F) Progression-free survival in relation to various
clinicopathological features of HCC patients. Data is displayed as hazard ratio with 95% confidence intervals. (D–F) Red plots highlight clinicopathological parameters
in which statistical significance was achieved. *, ** and *** indicate statistical significance where p ≤ 0.05, p ≤ 0.01 or p ≤ 0.005, respectively. Data in this Figure was
generated with use of KM Plotter (http://kmplot.com/analysis/).
when compared to non-tumorous tissues (Figure S1). Next,
we confirmed the downregulation of SCARF1 expression
in tumors at the protein level by immunohistochemical
staining of HCC tumors and matched distal, non-tumorous
tissues (Figure 1C). Surface area quantification of SCARF1
staining in matched samples from several patients showed
a significant (p ≤ 0.01) reduction in SCARF1 expression
in tumor tissues, when compared to distal, non-tumorous
tissues (Figure 1D).
Loss of SCARF1 Expression Is Associated
With More Advanced and Aggressive
Tumors
Previously, we have shown that the level of
immunohistochemical staining of SCARF1 in poorly
differentiated HCC tumor tissues was greatly reduced when
compared with well- and moderately-differentiated tumors
(14); here, we aimed to utilize the TGCA dataset to further
corroborate those findings. Differentiation status of solid tumors
informs their histological grading and, consequently, gives
an indication of tumor aggressiveness; therefore, we initially
explored the expression of SCARF1 in HCC tumors of different
histological grades. In doing this, we showed significantly
reduced levels in Grade 3 (p ≤ 0.05) and Grade 4 (p ≤ 0.01)
tumors, when compared to Grade 1 tumors (Figure 2A).
Next, we explored the SCARF1 expression levels in cases
of HCC at different stages of the disease, from early stage
disease (Stage I) through to highly developed and metastatic
disease (Stage IV). When compared to patients with Stage I
disease, cohorts of patients with Stages II, III and IV disease
all demonstrated a trend for decreased SCARF1 expression;
however, only the data for the Stage II cohort was calculated
to be statistically significant (p ≤ 0.01) (Figure 2B). We
further aimed to confirm these findings by correlating SCARF1
expression with other parameters commonly associated with
increased tumor aggressiveness and grade, in particular, we
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FIGURE 4 | SCARF1 is expressed in HCC tumor endothelial cells. (A) Correlation of scavenger receptor gene expression with tumor-associated cell-specific markers.
This analysis was performed via the cBioPortal website (https://www.cbioportal.org/) (accessed 10th August 2020). n = 358. The heatmap was generated with use of
the Heatmapper website (http://www.heatmapper.ca/). The black box highlights the expression profile of SCARF1. (B) Representative image of dual color
immunofluorescent staining of SCARF1 (green) and CD31 (red) within HCC tumor sinusoids. Scale bar = 40µm. White dashed line delineates site of intensity
measurements. (C) Intensity measurements of immunofluorescent staining shown in (B).
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focussed on Aneuploidy Score (38) and Buffa Hypoxia Score
(39). In both instances, SCARF1 expression demonstrated
a moderate negative correlation in HCC tumor tissues
(Figures 2C,D), thus providing further evidence that a loss
of SCARF1 expression is associated with adverse biology and
aggressive HCC tumors.
Prognostic Value of SCARF1 Expression in
HCC
Having found that a loss of SCARF1 expression correlates
with more advanced and aggressive tumors, we next sought to
investigate its prognostic value in HCC. With regards to overall
survival, high expression of SCARF1 was highly indicative of a
better prognosis (HR = 0.60, 95% CI = 0.42–0.86, p ≤ 0.01;
Figure 3A and Figure S2. Interestingly, with the exception of
ASGR1, which is expressed in HCC tumor cells and known to
prevent metastasis (40), SCARF1 was the only other scavenger
receptor gene which was associated with increased survival
in HCC (Figure S2). A high expression of SCARF1 was also
associated with a better prognosis when disease-free survival
(HR = 0.60, 95% CI = 0.48–0.93, p ≤ 0.05; Figure 3B) and
progression-free survival (HR = 0.59, 95% CI = 0.44–0.80,
p ≤ 0.01; Figure 3C) were considered. We also assessed the
prognostic value of SCARF1 expression in correlation with a
range of clinicopathological features. In male patients, higher
SCARF1 expression was suggestive of better overall survival
(HR = 0.53, 95% CI = 0.34–0.84, p ≤ 0.005; Figure 3D),
disease-free survival (HR = 0.64, 95% CI = 0.43–0.95, p ≤
0.05; Figure 3E) and progression-free survival (HR = 0.54,
95% CI = 37–0.78, p ≤ 0.005; Figure 3F), but, surprisingly,
showed no prognostic value in female patients (Figures 3D–F).
In Asian patient cohorts, higher SCARF1 expression was strongly
associated with better overall (HR = 0.46, 95% CI = 0.24–
0.85, p ≤ 0.05; Figure 3D), disease-free (HR = 0.56, 95% CI
= 0.34–0.94, p ≤ 0.05; Figure 3E) and progression-free (HR
= 0.55, 95% CI = 0.34–0.89, p ≤ 0.05; Figure 3F) survival;
however, in white patients it was indicative of better overall
(HR = 0.59, 95% CI = 0.36–0.95, p ≤ 0.05; Figure 3D) and
progression-free survival (HR = 0.63, 95% CI = 0.42–0.93, p ≤
0.05; Figure 3F), but not disease-free survival (Figure 3E). With
regards to histological grade of HCC tumors, a higher SCARF1
expression was strongly associated with better overall survival
(HR = 0.21, 95% CI = 0.07–0.68, p ≤ 0.005; Figure 3D) and
progression-free survival (HR = 0.38, 95% CI = 0.17–0.86, p ≤
0.05; Figure 3F) in Grade 1 tumors, but held no prognostic value
for disease-free survival (Figure 3E). High expression of SCARF1
in Grade 2 HCC tumors was again indicative of improved overall
survival (HR = 0.47, 95% CI = 0.27–0.81, p ≤ 0.05; Figure 3D)
and progression-free survival (HR = 0.55, 95% CI = 0.34–
0.89, p ≤ 0.05; Figure 3F), but showed no effect on disease-
free survival (Figure 3E). Higher SCARF1 expression in Grade
3 HCC tumors was only associated with better progression-free
survival (HR = 0.60, 95% CI = 0.36–0.98, p ≤ 0.05; Figure 3F),
but had no prognostic value for overall (Figure 3D) or disease-
free survival (Figure 3E). SCARF1 expression was, however,
highly prognostic of better overall survival (HR = 0.46, 95% CI
= 0.28–0.74, p ≤ 0.005), disease-free survival (HR = 0.49, 95%
CI = 0.29–0.81, p ≤ 0.01) and progression-free survival (HR =
0.51, 95% CI = 0.32–0.79, p ≤ 0.01) in patients with non-viral
HCC, but exhibited no prognostic value in viral HCC patients.
Furthermore, expression of SCARF1 showed no prognostic value
with regards to cancer staging or in the presence/absence of
vascular invasion (Figures 3D–F).
HCC Tumor-Expressed SCARF1 Exhibits a
Strong Endothelial Signature
To explore the cell-specific expression of SCARF1 within HCC
tumors, we correlated the gene expression of the scavenger
receptor superfamily with a number of gene sets known to
be expressed in tumor-associated cell populations (41–44).
Interestingly, of the entire scavenger receptor superfamily,
SCARF1 demonstrated the most endothelial-specific signature
within HCC tumor tissues, exhibiting low to moderate
correlations with the majority of the other cell type gene sets
(Figure 4A). We next utilized the publically-available tool
Gene Expression Profiling Interactive Analysis (GEPIA;
http://gepia.cancer-pku.cn/) to generate a list of genes
commonly regulated in conjunction with SCARF1 within
HCC tumor tissues (Table S1). Out of the top 25 hits, a
number of genes were endothelial-specific and we selected
some of these to further explore their relationship with
SCARF1 expression. Consequently, all of the endothelial
markers selected (ADGRF5, CD93, FLT4, MMRN2, ESAM,
PEAR1, PECAM1, TIE1, and CLEC14A) exhibited a highly
significant positive correlation with SCARF1 expression
(Figure S3). Next, to corroborate the expression of SCARF1
in tumor sinusoidal endothelial cells we undertook dual
immunofluorescence staining of SCARF1 and CD31, a
commonly used tumor endothelial marker known to be
expressed in HCC (42, 45). Within HCC tumor tissue, we
demonstrated a strong co-localization of SCARF1 and CD31
(Figures 4B,C).
SCARF1 Preferentially Supports Adhesion
of CD4+CD25− “Effector” T Cells to Human
Liver Endothelial Cells
Having previously shown that SCARF1 mediates the specific
recruitment of CD4+ T cells to LSEC in vitro, under conditions
of physiological flow (14), we aimed to determine whether
it could play a role in the recruitment of TILs to the HCC
tumor microenvironment. Firstly, and again utilizing the
data available on the cBioPortal website, we correlated the
expression of SCARF1 with CD4 expression and showed a
moderate positive correlation between the two (Figure 5A).
We next used a publically-available tool, Tumor IMmune
Estimation Resource (TIMER; https://cistrome.shinyapps.
io/timer/) to correlate SCARF1 expression with the level of
CD4+ T cell infiltration of HCC tumors. Using TIMER, we
confirmed that SCARF1 expression is absent from tumor
cells, as indicated by a negative “purity” correlation (−0.295;
Figure 5B, left panel), and demonstrated a moderate positive
correlation with CD4+ T cell infiltration (purity-corrected
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FIGURE 5 | SCARF1 potentially mediates the recruitment of proinflammatory CD4+ T cells to HCC tumors. (A) Correlation of SCARF1 expression with CD4
expression in HCC tumor tissues. n = 358. (B) Correlation of SCARF1 expression with the extent of CD4+ T cell infiltration in HCC tumor tissues. n = 358. (C)
Schematic representation of a flow-based adhesion assay with primary human lymphocytes flowed across primary human LSEC. (D) Quantification of percentage of
adherent CD4+ T cell subsets [regulatory (CD4+CD25+) and effector (CD4+CD25−)] in the presence of SCARF1 blocking antibody or isotype-matched control
(Control) antibody. **** indicates statistical significance as measured by a paired T-test, where p ≤ 0.001. n = 3 independent experiments with different LSEC and
lymphocyte donors, with 12 fields of view taken from each. Data in (B) was generated with use of Tumor IMmune Estimation Resource (TIMER; https://cistrome.
shinyapps.io/timer/; accessed 12th May 2020). Image in (C) created with BioRender.com.
partial Spearman’s rho value = 0.420, p = 3.79e−16; Figure 5B,
right panel). The balance of immune subsets within the tumor
microenvironment plays a critical role in tumor development
and progression, with an immunosuppressive microenvironment
promoting immune escape and a poor prognosis (46).
To assess if SCARF1 could functionally contribute to the
balance of immune effector vs. immunosuppressive subsets
within the tumor microenvironment, we studied its role
in CD4+ T cell subset recruitment. Using flow-based
adhesion assays under conditions of physiological shear
stress with primary human LSEC and purified populations
of primary human CD4+ T cells (Figure 5C), we showed
that antibody blockade of SCARF1 on LSEC had a significant
(∼40%; p ≤ 0.001) inhibitory effect on the adhesion of
proinflammatory (CD4+CD25−) T cells (effectors), but a
negligible (∼10%) effect on regulatory (CD4+CD25+) T cells
(Tregs) (Figure 5D).
DISCUSSION
Hepatocellular carcinoma (HCC) predominantly manifests on a
background of cirrhosis and, consequently, in conjunction with
the global rise in chronic liver diseases, incidence of HCC is
also set to rise. Novel medical therapies are urgently required
as patients often present to clinic with advanced tumors without
curative options (47). Recently, immunotherapies have provided
a number of very promising prospects in the treatment of
a wide range of cancers; in particular, checkpoint inhibitors
and chimeric antigen receptor (CAR)-T cell therapy have
received significant attention. Checkpoint inhibitors aim to
Frontiers in Oncology | www.frontiersin.org 9 September 2020 | Volume 10 | Article 565950
Patten et al. SCARF1 in Hepatocellular Carcinoma
FIGURE 6 | Schematic representation of potential mechanism of action of SCARF1 in HCC tumors. (A) In the presence of high expression of SCARF1 in tumor
endothelial cells, proinflammatory CD4+CD25− T cells are recruited to HCC tumors, resulting in decreased tumor development and, ultimately, decreased mortality.
(B) In low expression of SCARF1 in tumor endothelial cells, recruitment of CD4+CD25− T cells lower, resulting in increased tumor development and mortality. Image
created with BioRender.com.
release the “brake” from the immune system, thus allowing a
robust anti-tumoral host immune response (48, 49) and CAR-
T cells are genetically-engineered T cells specifically designed
to recognize tumor antigen-expressing cells and subsequently
kill them (50). However, in solid organ tumors, both these
approaches are reliant on leukocyte trafficking to the tumor
and this remains a significantly under-studied aspect of cancer
immunotherapy (51). In the liver, leukocyte trafficking occurs
within the microvasculature, known as the hepatic sinusoids.
The low shear environment leads to a unique adhesion
cascade with the lack of selectin-mediated recruitment and a
number of atypical adhesion receptors involved in immune
cell recruitment to liver sinusoidal endothelial cells (LSEC).
Our previous studies have explored immune cell recruitment
in the context of chronic inflammatory liver diseases, with
a particular focus on LSEC-expressed scavenger receptors;
however, we have also identified members of the scavenger
receptor family which are expressed in vivo on the endothelium
of human HCC, thus suggesting that they may also contribute
to immune cell recruitment to the tumor microenvironment
(13, 14).
Scavenger receptors represent a major subset of innate
pattern recognition receptors able to bind a number of cancer-
relevant ligands, such as heat shock proteins (HSPs) (52,
53) and bacterial lipopolysaccharide (LPS) (54–56), and are
known to be involved in the pathophysiology of a range
of cancers, including HCC (19). Interestingly, the expression
of a number of scavenger receptors is often associated with
poor prognosis and less favorable clinicopathological features
in HCC. For example, increased expression of CD68 and
CD163, which is indicative of increased numbers of anti-
inflammatory macrophages, is associated with poor overall and
disease-free survival (57, 58). In addition, upregulation of the
CXCL16-CXCR6 axis was associated with increased invasiveness
and recurrence and, as a consequence, was also associated
with poorer survival in HCC (59). In contrast to this, we
show that higher intratumoral expression of SCARF1 in HCC
was associated with less advanced and less aggressive cancers
(Figure 2). In addition, from a prognostic perspective, higher
SCARF1 expression in HCC tumors was highly indicative
of better overall, disease-free and progression-free survival
(Figure 3).
Consistent with our previous findings in normal and
chronically diseased liver tissues (14), SCARF1 in HCC
tumor tissues exhibited a highly sinusoidal expression pattern
(Figure 1C) and correlation data from the TGCA dataset further
corroborated its largely endothelial expression (Figure 4A). A
number of the top 25 genes commonly regulated in conjunction
with SCARF1 within HCC tumor tissues were endothelial-
specific (Table S1) and all demonstrated a strong positive
correlation with levels of SCARF1 expression (Figure S2). We
were able to confirm protein expression of SCARF1 in tumoral
sinusoidal endothelial cells through dual immunofluorescence
staining with the common endothelial marker CD31 (Figure 4B)
and subsequent co-localization of the two proteins (Figure 4C).
Having previously shown that SCARF1 mediates the specific
recruitment of CD4+ T cells to LSEC in inflammatory conditions
(14), we next explored whether it could play a role in the
recruitment of TILs to the HCC tumor microenvironment. We
found that SCARF1 expression showed a positive correlation with
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both CD4 expression (Figure 5A) and the level of CD4+ T cell
infiltration of HCC tumors (Figure 5B, right panel). Given that a
loss of SCARF1 expression was associated with more advanced
and aggressive HCC tumors and that increased expression
was highly prognostic of better survival, we hypothesized that
SCARF1 could potentially be playing a beneficial role in the
pathophysiology of HCC by shaping the immune infiltration
of the tumor microenvironment (60). We used primary human
LSEC in flow-based adhesion assays with CD4+ T cells
subsets and showed that antibody blockade of SCARF1 could
indeed significantly inhibit the adhesion of proinflammatory
(CD4+CD25−) T cells (effectors), but had little effect the
adhesion of regulatory (CD4+CD25+) T cells (Tregs). This is in
direct contrast to our previous work on another endothelial-
expressed scavenger receptor, Stabilin-1, which is also present
in HCC tumors, but plays a role in the specific recruitment of
anti-inflammatory regulatory (CD4+CD25+) T cells (13).
These findings highlight the potential role of SCARF1
expression as a prognostic biomarker in HCC. Down regulation
of SCARF1 was associated with a poorer outcome and
interestingly this may be a relevant to other tumors as we
showed that tumors of other gastrointestinal cancers, such
as esophageal, gastric and colonic cancers, also significantly
down-regulated SCARF1 expression (Figure S1). In addition to
high SCARF1 expression correlating with a good outcome, our
functional assays also suggest that SCARF1 may have an active
anti-tumoral role for by promoting the recruitment of effector
CD4+ T cells rather than tumor promoting regulatory T cells
(Tregs). This is particularly pertinent as previous studies have
specifically shown that an increased prevalence of Tregs is an
independent prognostic factor in HCC; therefore, shifting this
balance could have a significant impact on patient outcome
(61). In contrast to other GI malignancies, we found that
pancreatic adenocarcinoma tumor tissues exhibited comparable
SCARF1 expression to non-tumorous tissues (Figure S1). This
could be due to the fact that pancreatic tumors are inherently
and notoriously immunogenically “cold” tumors, due to a
combination of low neoantigenic burden, heterogeneous dense
stroma and an immunosuppressive tumor microenvironment
(62). Therefore, an active downregulation of SCARF1 expression,
in order to provide more favorable tumorigenic conditions, may
not play a role in the pathogenesis of this tumor.
Whilst immunotherapy has shown exciting results in
subgroups of HCC patients, there is limited stratification to
support the selection of these subgroups. The correlation of
SCARF1 with CD4+ T cell tumor infiltration and its role in
recruitment may help in the identification of patients who
will respond to immunotherapies. However, further in vivo
work is now required with SCARF1 knockout models to
confirm the extent of its contribution to the HCC immune
microenvironment. In addition, the identity of the receptor
for SCARF1 present on CD4+CD25− lymphocytes remains
unknown, thus further studies are also required to identify its
ligand. Furthermore, SCARF1 is primarily a scavenger receptor,
and so the impact of its presence with regards to its scavenging
function also needs to be considered in future studies. SCARF1
has been shown to bind a range of endogenous ligands, such
as oxidized lipoproteins (21), heat shock proteins (23–25)
and apoptotic cells (26, 27), and regulate LPS responses (35);
therefore, all these functions could also potentially influence
the tumor microenvironment. For example, the uptake of these
factors by SCARF1 could prevent neutrophil and macrophage
accumulation in the tumor microenvironment, thus providing
an alternative mode-of-action for the anti-tumoral action of
SCARF1, as myeloid cell accumulation is often associated with
poor prognosis in HCC (63, 64). Nevertheless, our data here
show that SCARF1 could potentially support the recruitment
of proinflammatory (CD4+CD25−) T cells to HCC tumors,
leading to decreased tumoral progression and, ultimately, a
better overall outcome (Figure 6). Our findings also suggest
that future agonistic agents acting to increase the expression
of SCARF1 within tumors could boost the numbers of tumor-
infiltrating proinflammatory lymphocytes. Further experimental
studies of SCARF1 could therefore lead to novel combination
immunotherapeutic strategies in HCC as well as in other
gastrointestinal tumors.
DATA AVAILABILITY STATEMENT
The raw data supporting the conclusions of this article will be
made available by the authors, without undue reservation.
ETHICS STATEMENT
The studies involving human participants were reviewed and
approved byWest Midlands–South Birmingham Research Ethics
Committee. The patients/participants provided their written
informed consent to participate in this study.
AUTHOR CONTRIBUTIONS
DP: conceptualization, formal analysis, and writing–original
draft. DP, AW, and JO’R: data curation and investigation. DP and
SS: funding acquisition, methodology, and writing–review and
editing. All authors contributed to the article and approved the
submitted version.
FUNDING
DP and SS are funded by a Medical Research Council
Project Grant (MR/R010013/1) and a Rosetrees Trust Research
Grant. AW is funded by a Well-come Trust PhD studentship
(Mechanisms of Inflammatory Diseases (MIDAS) scheme).
JO’R is supported by HUNTER, funded through a partnership
between Cancer Research UK, Fondazione AIRC and Fundacion
Cientifica de la Asociacion Espanola Contra el Cancer.
ACKNOWLEDGMENTS
We thank Dr. Gary Reynolds for his technical assistance. We also
thank the patients and clinical staff from the Queen Elizabeth
Hospital, Birmingham, for donation and collection of tissue and
blood. This paper presents independent research supported by
Frontiers in Oncology | www.frontiersin.org 11 September 2020 | Volume 10 | Article 565950
Patten et al. SCARF1 in Hepatocellular Carcinoma
the Birmingham NIHR Liver Biomedical Research Unit based
at the University Hospitals Birmingham NHS Foundation Trust
and the University of Birmingham. The views expressed are those
of the authors and not necessarily those of the NHS, the NIHR or
the Department of Health.
SUPPLEMENTARY MATERIAL




1. Bertuccio P, Turati F, Carioli G, Rodriguez T, La Vecchia C, Malvezzi M,
et al. Global trends and predictions in hepatocellular carcinoma mortality. J
Hepatol. (2017) 67:302–9. doi: 10.1016/j.jhep.2017.03.011
2. Debes JD, Carrera E, Mattos AZ, Prieto JE, Boonstra, A. Hepatocellular
carcinoma, a unique tumor with a lack of biomarkers. Ann Hepatol. (2019)
18:786–7. doi: 10.1016/j.aohep.2019.07.009
3. O’Rourke JM, Sagar VM, Shah T, Shetty, S. Carcinogenesis on the background
of liver fibrosis: implications for the management of hepatocellular
cancer. World J Gastroenterol. (2018) 24:4436–47. doi: 10.3748/wjg.v24.i39.
4436
4. Zhang JP, Yan J, Xu J, Pang XH, Chen MS, Li L, et al. Increased intratumoral
IL-17-producing cells correlate with poor survival in hepatocellular carcinoma
patients. J Hepatol. (2009) 50:980–9. doi: 10.1016/j.jhep.2008.12.033
5. Yao W, He JC, Yang Y, Wang JM, Qian YW, Yang T, et al. The
prognostic value of tumor-infiltrating lymphocytes in hepatocellular
carcinoma: a systematic review and meta-analysis. Sci Rep. (2017)
7:7525. doi: 10.1038/s41598-017-08128-1
6. Gao Q, Qiu SJ, Fan J, Zhou J, Wang XY, Xiao YS, et al. Intratumoral
balance of regulatory and cytotoxic T cells is associated with prognosis
of hepatocellular carcinoma after resection. J Clin Oncol. (2007) 25:2586–
93. doi: 10.1200/JCO.2006.09.4565
7. Greten TF, Sangro, B. Targets for immunotherapy of liver cancer. J Hepatol.
(2018) 68:157–66. doi: 10.1016/j.jhep.2017.09.007
8. Prieto J, Melero I, Sangro, B. Immunological landscape and immunotherapy
of hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol. (2015) 12:681–
700. doi: 10.1038/nrgastro.2015.173
9. Hilmi M, Neuzillet C, Calderaro J, Lafdil F, Pawlotsky JM, et al. Angiogenesis
and immune checkpoint inhibitors as therapies for hepatocellular carcinoma:
current knowledge and future research directions. J Immunother Cancer.
(2019) 7:333. doi: 10.1186/s40425-019-0824-5
10. Shetty S, Lalor PF, Adams, D.H. Liver sinusoidal endothelial cells—
gatekeepers of hepatic immunity. Nat Rev Gastroenterol Hepatol. (2018)
15:555–67. doi: 10.1038/s41575-018-0020-y
11. Patten DA, Shetty, S. More than just a removal service: scavenger
receptors in leukocyte trafficking. Front Immunol. (2018)
9:2904. doi: 10.3389/fimmu.2018.02904
12. Patten DA, Wilson GK, Bailey D, Shaw RK, Jalkanen S, Salmi M, et al.
Human liver sinusoidal endothelial cells promote intracellular crawling of
lymphocytes during recruitment: a new step in migration. Hepatology. (2017)
65:294–309. doi: 10.1002/hep.28879
13. Shetty S, Weston CJ, Oo YH, Westerlund N, Stamataki Z, Youster
J, et al. Common lymphatic endothelial and vascular endothelial
receptor-1 mediates the transmigration of regulatory T cells
across human hepatic sinusoidal endothelium. J Immunol. (2011)
186:4147–55. doi: 10.4049/jimmunol.1002961
14. Patten DA, Kamarajah SK, Rose JM, Tickle J, Shepherd EL, Adams DH,
et al. SCARF-1 promotes adhesion of CD4+ T cells to human hepatic
sinusoidal endothelium under conditions of shear stress. Sci Rep. (2017)
7:17600. doi: 10.1038/s41598-017-17928-4
15. Jung MY, Park SY, Kim IS. Stabilin-2 is involved in lymphocyte adhesion to
the hepatic sinusoidal endothelium via the interaction with αMβ2 integrin. J
Leuk Biol. (2007) 82:1156–65. doi: 10.1189/jlb.0107052
16. Patten DA, Shetty, S. The role of Stabilin-1 in lymphocyte trafficking and
macrophage scavenging in the liver microenvironment. Biomolecules. (2019)
9:283. doi: 10.3390/biom9070283
17. Canton J, Neculai D, Grinstein, S. Scavenger receptors in homeostasis and
immunity. Nat Rev Immunol. (2013) 13:621–34. doi: 10.1038/nri3515
18. Armengol C, Bartoli R, Sanjurjo L, Serra I, Amezaga N, Sala M, et al. Role of
scavenger receptors in the pathophysiology of chronic liver diseases. Crit Rev
Immunol. (2013) 33:57–96. doi: 10.1615/CritRevImmunol.2013006794
19. Yu X, Guo C, Fisher PB, Subjeck JR, Wang XY. Scavenger receptors: emerging
roles in cancer biology and immunology. Adv Cancer Res. (2015) 128:309–
64. doi: 10.1016/bs.acr.2015.04.004
20. Adachi H, Tsujimoto M, Arai H, Inoue, K. Expression cloning of a novel
scavenger receptor from human endothelial cells. J Biol Chem. (1997)
272:31217–20. doi: 10.1074/jbc.272.50.31217
21. Tamura Y, Osuga JI, Adachi H, Tozawa RI, Takanezawa Y, Ohashi
K, et al. Scavenger receptor expressed by endothelial cells I (SREC-I)
mediates the uptake of acetylated low density lipoproteins by macrophages
stimulated with lipopolysaccharide. J Biol Chem. (2004) 279:30938–
44. doi: 10.1074/jbc.M313088200
22. Patten DA. SCARF1: a multifaceted, yet largely understudied, scavenger
receptor. Inflam Res. (2018) 67:627–32. doi: 10.1007/s00011-018-1154-7
23. Murshid A, Gong J, Calderwood SK. Hsp90–peptide complexes
stimulate antigen presentation through the class II pathway
after binding scavenger receptor SREC-I. Immunobiology. (2014)
219:924–31. doi: 10.1016/j.imbio.2014.08.001
24. Facciponte JG, Wang XY, Subjeck JR. Hsp110 and Grp170, members
of the Hsp70 superfamily, bind to scavenger receptor-A and scavenger
receptor expressed by endothelial cells-I. Eur J Immunol. (2007) 37:2268–
79. doi: 10.1002/eji.200737127
25. Gong J, Zhu B, Murshid A, Adachi H, Song B, Lee A, et al. T cell activation
by heat shock protein 70 vaccine requires TLR signaling and scavenger
receptor expressed by endothelial cells-1. J Immunol. (2009) 183:3092–
98. doi: 10.4049/jimmunol.0901235
26. Ramirez-Ortiz ZG, Pendergraft III WF, Prasad A, Byrne MH, Iram T,
Blanchette CJ, et al. The scavenger receptor SCARF1 mediates the clearance
of apoptotic cells and prevents autoimmunity. Nat Immunol. (2013) 14:917–
26. doi: 10.1038/ni.2670
27. Wicker-Planquart C, Dufour S, Tacnet-Delorme P, Bally I, Delneste Y, Frachet
P, et al. Molecular and cellular interactions of scavenger receptor SR-F1 with
complement C1q provide insights into its role in the clearance of apoptotic
cells. Front Immunol. (2020) 11:544. doi: 10.3389/fimmu.2020.00544
28. Beauvillain C, Meloni F, Sirard JC, Blanchard S, Jarry U, Scotet M, et al.
The scavenger receptors SRA-1 and SREC-I cooperate with TLR2 in the
recognition of the hepatitis C virus non-structural protein 3 by dendritic cells.
J Hepatol. (2010) 52:644–51. doi: 10.1016/j.jhep.2009.11.031
29. Murshid A, Gong J, Ahmad R, Borges TJ, Calderwood SK.
Scavenger receptor SREC-I promotes double stranded RNA-mediated
TLR3 activation in human monocytes. Immunobiology. (2015)
220:823–32. doi: 10.1016/j.imbio.2014.12.011
30. Piccolo P, Vetrini F, Mithbaokar P, Grove NC, Bertin T, Palmer D, et al. SR-A
and SREC-I are Kupffer and endothelial cell receptors for helper-dependent
adenoviral vectors.Mol Ther. (2013) 21:767–74. doi: 10.1038/mt.2012.287
31. Means TK, Mylonakis E, Tampakakis E, Colvin RA, Seung E, Puckett L,
et al. Evolutionarily conserved recognition and innate immunity to fungal
pathogens by the scavenger receptors SCARF1 and CD36. J Exp Med. (2009)
206:637–53. doi: 10.1084/jem.20082109
32. Rechner C, Kühlewein C, Müller A, Schild H, Rudel T. Host glycoprotein
Gp96 and scavenger receptor SREC interact with PorB of disseminating
Neisseria gonorrhoeae in an epithelial invasion pathway. Cell Host Microbe.
(2007) 2:393–403. doi: 10.1016/j.chom.2007.11.002
33. Jeannin P, Bottazzi B, Sironi M, Doni A, Rusnati M, Presta M, et al.
Complexity and complementarity of outer membrane protein A recognition
by cellular and humoral innate immunity receptors. Immunity. (2005) 22:551–
60. doi: 10.1016/j.immuni.2005.03.008
Frontiers in Oncology | www.frontiersin.org 12 September 2020 | Volume 10 | Article 565950
Patten et al. SCARF1 in Hepatocellular Carcinoma
34. Baur S, Rautenberg M, Faulstich M, Grau T, Severin Y, Unger C, et al. A
nasal epithelial receptor for Staphylococcus aureus WTA governs adhesion
to epithelial cells and modulates nasal colonization. PLoS Pathog. (2014)
10:e1004089. doi: 10.1371/journal.ppat.1004089
35. Murshid A, Gong J, Prince T, Borges TJ, Calderwood SK. Scavenger receptor
SREC-I mediated entry of TLR4 into lipid microdomains and triggered
inflammatory cytokine release in RAW 264.7 cells upon LPS activation. PLoS
ONE. (2015) 10:e0122529. doi: 10.1371/journal.pone.0122529
36. Lalor PF, Edwards S, McNab G, Salmi M, Jalkanen S, Adams DH.
Vascular adhesion protein-1 mediates adhesion and transmigration of
lymphocytes on human hepatic endothelial cells. J Immunol. (2002) 169:983–
92. doi: 10.4049/jimmunol.169.2.983
37. Shetty S, Weston CJ, Adams DH, Lalor PF. A flow adhesion assay to
study leucocyte recruitment to human hepatic sinusoidal endothelium under
conditions of shear stress. JoVE. (2014) 85:51330. doi: 10.3791/51330
38. Taylor AM, Shih J, Ha G, Gao GF, Zhang X, Berger AC, et al. Genomic
and functional approaches to understanding cancer aneuploidy. Cancer Cell.
(2018) 33:676–89. doi: 10.1016/j.ccell.2018.03.007
39. Buffa F, Harris A, West C, Miller, C. Large meta-analysis of multiple cancers
reveals a common, compact and highly prognostic hypoxia metagene. Br J
Cancer. (2010) 102:428–35. doi: 10.1038/sj.bjc.6605450
40. Gu D, Jin H, Jin G, Wang C, Wang N, Hu F, et al. The asialoglycoprotein
receptor suppresses the metastasis of hepatocellular carcinoma via LASS2-
mediated inhibition of V-ATPase activity. Cancer Letters. (2016) 379:107–
16. doi: 10.1016/j.canlet.2016.05.030
41. Cassetta L, Fragkogianni S, Sims AH, Swierczak A, Forrester
LM, Zhang H, et al. Human tumor-associated macrophage
and monocyte transcriptional landscapes reveal cancer-specific
reprogramming, biomarkers, and therapeutic targets. Cancer Cell. (2019)
35:588–602. doi: 10.1016/j.ccell.2019.02.009
42. Aizarani N, Saviano A, Mailly L, Durand S, Herman JS, Pessaux P, et al. et al. A
human liver cell atlas reveals heterogeneity and epithelial progenitors.Nature.
(2019) 572:199–204. doi: 10.1038/s41586-019-1373-2
43. Hubert M, Gobbini E, Bendriss-Vermare N, Caux C, Valladeau-Guilemond
J. Human tumor-infiltrating dendritic cells: From in situ visualization
to high-dimensional analyses. Cancers. (2019) 11:1082. doi: 10.3390/
cancers11081082
44. Costa A, Kieffer Y, Scholer-Dahirel A, Pelon F, Bourachot B, Cardon M, et
al. Fibroblast heterogeneity and immunosuppressive environment in human
breast cancer. Cancer Cell. (2018) 33:463–79. doi: 10.1016/j.ccell.2018.01.011
45. Qian H, Yang L, Zhao W, Chen, H, He S. A comparison of CD105
and CD31 expression in tumor vessels of hepatocellular carcinoma by
tissue microarray and flow cytometry. Exp Ther Med. (2018) 16:2881–
8. doi: 10.3892/etm.2018.6553
46. Rabinovich GA, Gabrilovich D, Sotomayor EM. Immunosuppressive
strategies that are mediated by tumor cells. Ann Rev Immunol. (2007) 25:267–
96. doi: 10.1146/annurev.immunol.25.022106.141609
47. Than NN, Ghazanfar A, Hodson J, Tehami N, Coldham C, Mergental H, et al.
Comparing clinical presentations, treatments and outcomes of hepatocellular
carcinoma due to hepatitis C and non-alcoholic fatty liver disease. QJM.
(2017) 110:73–81. doi: 10.1093/qjmed/hcw151
48. Sharpe AH. Introduction to checkpoint inhibitors and cancer
immunotherapy. Immunol Rev. (2017) 276:5–8. doi: 10.1111/imr.12531
49. Iwai Y, Hamanishi J, Chamoto K, Honjo, T. Cancer immunotherapies
targeting the PD-1 signaling pathway. J Biomed Sci. (2017)
24:26. doi: 10.1186/s12929-017-0329-9
50. Jackson HJ, Rafiq S, Brentjens RJ. Driving CAR T-cells forward. Nat Rev Clin
Oncol. (2016) 13:370–83. doi: 10.1038/nrclinonc.2016.36
51. Georganaki M, van Hooren L, Dimberg, A. Vascular targeting to increase the
efficiency of immune checkpoint blockade in cancer. Front Immunol. (2018)
9:3081. doi: 10.3389/fimmu.2018.03081
52. Calderwood SK, Gong, J. Heat shock proteins promote cancer: it’s a protection
racket. Trends Biochem Sci. (2016) 41:311–23. doi: 10.1016/j.tibs.2016.01.003
53. Wu J, Liu T, Rios Z, Mei Q, Lin X, Cao, et al. Heat shock proteins and cancer.
Trends Pharmacol Sci. (2017) 38:226–56. doi: 10.1016/j.tips.2016.11.009
54. Ikebe M, Kitaura Y, Nakamura M, Tanaka H, Yamasaki A, Nagai S, et al.
Lipopolysaccharide (LPS) increases the invasive ability of pancreatic cancer
cells through the TLR4/MyD88 signaling pathway. J Surg Oncol. (2009)
100:725–31. doi: 10.1002/jso.21392
55. Hsu RY, Chan CH, Spicer JD, Rousseau MC, Giannias B, Rousseau S, et
al. LPS-induced TLR4 signaling in human colorectal cancer cells increases
β1 integrin-mediated cell adhesion and liver metastasis. Cancer Res. (2011)
71:1989–98. doi: 10.1158/0008-5472.CAN-10-2833
56. Kisseleva T, Song L, Vorontchikhina M, Feirt N, Kitajewski J, Schindler, et
al. NF-κB regulation of endothelial cell function during LPS-induced toxemia
and cancer. J Clin Invest. (2006) 116:2955–63. doi: 10.1172/JCI27392
57. Kong LQ, Zhu XD, Xu HX, Zhang JB, Lu L, Wang WQ, et al.
The clinical significance of the CD163+ and CD68+ macrophages
in patients with hepatocellular carcinoma. PLoS ONE. (2013)
8:e59771. doi: 10.1371/journal.pone.0059771
58. Yeung OW, Lo CM, Ling CC, Qi X, Geng W, Li CX, et al.
Alternatively activated (M2) macrophages promote tumour growth
and invasiveness in hepatocellular carcinoma. J Hepatol. (2015)
62:607–16. doi: 10.1016/j.jhep.2014.10.029
59. Gao Q, Zhao YJ, Wang XY, Qiu SJ, Shi YH, Sun J, et al. CXCR6 upregulation
contributes to a proinflammatory tumor microenvironment that drives
metastasis and poor patient outcomes in hepatocellular carcinoma. Cancer
Res. (2012) 72:3546–56. doi: 10.1158/0008-5472.CAN-11-4032
60. Borst J, Ahrends T, Babała N, Melief CJ, Kastenmüller, W. CD4+ T cell
help in cancer immunology and immunotherapy. Nat Rev Immunol. (2018)
18:635–47. doi: 10.1038/s41577-018-0044-0
61. Tu JF, Ding YH, Ying XH, Wu FZ, Zhou XM, Zhang DK, et al. Regulatory
T cells, especially ICOS+ FOXP3+ regulatory T cells, are increased in the
hepatocellular carcinomamicroenvironment and predict reduced survival. Sci
Rep. (2016) 6:35056. doi: 10.1038/srep35056
62. Upadhrasta S, Zheng, L. Strategies in developing immunotherapy
for pancreatic cancer: recognizing and correcting multiple immune
“defects” in the tumor microenvironment. J Clin Med. (2019)
8:1472. doi: 10.3390/jcm8091472
63. Margetts J, Ogle LF, Chan SL, Chan AW, Chan KA, Jamieson D, et
al. Neutrophils: driving progression and poor prognosis in hepatocellular
carcinoma? Br J Cancer. (2018) 118:248–57. doi: 10.1038/bjc.2017.386
64. Yeung OW, Lo CM, Ling CC, Qi X, Geng W, Li CX, et al.
Alternatively activated (M2) macrophages promote tumour growth
and invasiveness in hepatocellular carcinoma. J Hepatol. (2015)
62:607–16. doi: 10.1016/j.jhep.2014.10.029
Conflict of Interest: SS has received a research grant from Faron Pharmaceuticals
to design a Phase I/II trial (TIETALC) of the drug “Clevergen” in patients with
HCC and also reports consulting for Faron Pharmaceuticals.
The remaining authors declare that the research was conducted in the absence of
any commercial or financial relationships that could be construed as a potential
conflict of interest.
Copyright © 2020 Patten, Wilkinson, O’Rourke and Shetty. This is an open-access
article distributed under the terms of the Creative Commons Attribution License (CC
BY). The use, distribution or reproduction in other forums is permitted, provided
the original author(s) and the copyright owner(s) are credited and that the original
publication in this journal is cited, in accordance with accepted academic practice.
No use, distribution or reproduction is permitted which does not comply with these
terms.
Frontiers in Oncology | www.frontiersin.org 13 September 2020 | Volume 10 | Article 565950
